<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer surgery outcomes &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cancer-surgery-outcomes/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Jan 2026 17:15:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Cancer surgery outcomes &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Preoperative Interleukin 2: Impact on Cancer Surgery Outcomes</title>
		<link>https://bioengineer.org/preoperative-interleukin-2-impact-on-cancer-surgery-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 17:15:35 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ameliyat öncesi dönemde (preoperatif)]]></category>
		<category><![CDATA[Cancer Immunomodulation** **Açıklama:** 1. **Preoperative Immunotherapy:** Makalenin temel odağı]]></category>
		<category><![CDATA[Cancer surgery outcomes]]></category>
		<category><![CDATA[en uygun 5 etiket: **Preoperative Immunotherapy]]></category>
		<category><![CDATA[Gastrointestinal cancer]]></category>
		<category><![CDATA[Gastrointestinal Cancer Surgery]]></category>
		<category><![CDATA[Interleukin 2]]></category>
		<category><![CDATA[Interleukin 2 Therapy]]></category>
		<category><![CDATA[Makale içeriği ve anahtar kelimeler göz önüne alındığında]]></category>
		<category><![CDATA[Meta-analysis]]></category>
		<category><![CDATA[Preoperative immunotherapy]]></category>
		<category><![CDATA[Surgical Oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/preoperative-interleukin-2-impact-on-cancer-surgery-outcomes/</guid>

					<description><![CDATA[Recent advancements in immunotherapy have generated considerable interest within the scientific community, particularly in the context of cancer treatment. One emergent focal point of this research is the role of recombinant Interleukin 2 (rIL-2) in preoperative immunomodulation, especially for patients undergoing gastrointestinal cancer surgery. A systematic review and meta-analysis led by Horcicka et al. aims [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317989</post-id>	</item>
	</channel>
</rss>
